Standard Biotools (LAB) Net Income towards Common Stockholders (2010 - 2026)

Standard Biotools (LAB) has reported Net Income towards Common Stockholders for 17 consecutive years, with $141.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 5420.84% year-over-year to $141.7 million; the TTM figure through Mar 2026 stood at $87.2 million (up 341.11% YoY), while the FY2025 annual figure was -$74.9 million, up 45.31% from the prior year.
• Net Income towards Common Stockholders advanced to $141.7 million in Q1 2026 per LAB's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $153.2 million in Q4 2022 and bottomed at -$76.3 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$2.2 million across 5 years, with a median of -$17.7 million in 2025.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 305.96% — and 2026, when it soared 5420.84%.
• Standard Biotools' Net Income towards Common Stockholders stood at $153.2 million in 2022, then tumbled by 90.78% to $14.1 million in 2023, then fell by 1.78% to $13.9 million in 2024, then sank by 115.63% to -$2.2 million in 2025, then surged by 6632.69% to $141.7 million in 2026.
• Business Quant data shows LAB's Net Income towards Common Stockholders at $141.7 million in Q1 2026, -$2.2 million in Q4 2025, and -$34.7 million in Q3 2025.